Akebia Therapeutics (AKBA) Stock Price, Quote & News

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phospho...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 871 2098

Fax: 617 871 2099

Website: www.akebia.com

Address:

245 First Street, Suite 1400, Cambridge, United States

Mr_Pithy Aug. 5 at 7:07 PM

$AKBA 61.85%, 75.47%, 216.88%, 827.16% increases. What’ll next 3 years look like w/ Vafseo DD revenues? $5B Vafseo NDD? Pipeline (AKB 9090 AKI/ARDS, AKB 10108 BPD/ROP, Praliciguat, Auryxia Europe, VADA DD/NDD Canada/China/LA …?

0 · Reply

Thickhog81 Aug. 5 at 7:07 PM

$AKBA soon!!! 🤑🚀🤑🚀

0 · Reply

Aamadeus Aug. 5 at 7:04 PM

$AKBA this is frustrating but not surprising with no volumes

0 · Reply

Mr_Pithy Aug. 5 at 6:56 PM

$AKBA 2 DAYS BEFORE EARNINGS REPORT, 19 WALL STREET ANALYSTS ARE FORECASTING $13.32 AKBA PRICE TARGET INDICATING 256.63% INCREASE. IMO THE FORECAST WILL NEED TO BE ADJUSTED UPWARD.

0 · Reply

Mr_Pithy Aug. 5 at 6:48 PM

$AKBA RECENT WHALE 🐳 ACTIVITY - 27 OUT OF 31 WHALES ARE BUYING AND HOLDING. NOT ALL WHALES 🐳 ARE PLAYING THRU EARNINGS THO’. SOME ARE CHICKENSHIT.

0 · Reply

Bulltrader988 Aug. 5 at 6:46 PM

$AKBA thursday pre market 👃👀

0 · Reply

Bidzill Aug. 5 at 6:39 PM

$AKBA Nearly symmetrical:

2 · Reply

Mr_Pithy Aug. 5 at 6:37 PM

$AKBA STANDING IN THIS CORNER - TipRanks $47.6M, Seeking Alpha $47.3M, Financhill $47.2M, Jefferies $46M. (Average $47.025M). STANDING IN THIS CORNER - @hsainu $100M, @Free_Hornz $113M, @skyhopes $114.8M. (Average $109.27M). AND THE WINNER IS … TBD.

2 · Reply

Solfer Aug. 5 at 6:35 PM

$AKBA I can see now what's happening here.. A couple of years ago I noticed bots on X were duplicating random ST posts, and reposting on X using fake accounts. It look like they're still doing the same, but this time asking AI to rewrite the ST post so it appears to be original content. However, in this case when they latched onto @Hsainu's post, AI didn't do its job and basically copied it verbatum! Below is another post on X by the same fake account, this time AI managed to ever so slightly change the wording of the ST post.. As for the point of all this fakery...? I've got no idea whatsoever!!

0 · Reply

Hogtrader1 Aug. 5 at 6:35 PM

$AKBA this is the most anticipated earnings release I can remember.

0 · Reply

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Aug 1, 2025, 4:05 PM EDT - 3 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2025, 8:00 AM EDT - 5 days ago

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Jul 8, 2025, 8:00 AM EDT - 4 weeks ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 1, 2025, 4:05 PM EDT - 4 weeks ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 4, 2025, 8:00 AM EDT - 2 months ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

May 28, 2025, 8:00 AM EDT - 2 months ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 27, 2025, 8:00 AM EDT - 2 months ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 13, 2025, 8:00 AM EDT - 3 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 12:44 PM EDT - 3 months ago

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 3 months ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 8:00 AM EDT - 3 months ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

Apr 3, 2025, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Mar 25, 2025, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 20, 2025, 8:18 AM EDT - 4 months ago

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

MCHP

Mar 19, 2025, 10:17 PM EDT - 4 months ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 4 months ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 13, 2025, 10:21 AM EDT - 5 months ago

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:00 AM EDT - 5 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 6, 2025, 8:00 AM EST - 5 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Feb 10, 2025, 5:43 AM EST - 6 months ago

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Jan 13, 2025, 8:00 AM EST - 7 months ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Dec 18, 2024, 8:00 AM EST - 8 months ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 7:00 AM EST - 8 months ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Nov 25, 2024, 8:00 AM EST - 9 months ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 20, 2024, 3:31 PM EST - 9 months ago

Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 14, 2024, 8:00 AM EST - 9 months ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Nov 12, 2024, 8:00 AM EST - 9 months ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 1:59 PM EST - 9 months ago

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 9 months ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 1, 2024, 8:00 AM EDT - 9 months ago

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

Oct 22, 2024, 8:00 AM EDT - 10 months ago

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Oct 15, 2024, 8:00 AM EDT - 10 months ago

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

Oct 10, 2024, 8:00 AM EDT - 10 months ago

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

Oct 7, 2024, 8:00 AM EDT - 10 months ago

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Sep 5, 2024, 8:00 AM EDT - 11 months ago

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Aug 10, 2024, 1:00 AM EDT - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 2, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

Jul 11, 2024, 6:00 AM EDT - 1 year ago

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Jun 27, 2024, 8:18 AM EDT - 1 year ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Jun 24, 2024, 8:58 AM EDT - 1 year ago

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

May 23, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference

May 9, 2024, 10:54 AM EDT - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 2, 2024, 8:30 AM EDT - 1 year ago

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights

Apr 4, 2024, 5:56 PM EDT - 1 year ago

Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management

Mar 27, 2024, 8:45 PM EDT - 1 year ago

U.S. FDA approves Akebia's anemia drug

Mr_Pithy Aug. 5 at 7:07 PM

0 · Reply

Thickhog81 Aug. 5 at 7:07 PM

$AKBA soon!!! 🤑🚀🤑🚀

0 · Reply

Aamadeus Aug. 5 at 7:04 PM

$AKBA this is frustrating but not surprising with no volumes

0 · Reply

Mr_Pithy Aug. 5 at 6:56 PM

$AKBA 2 DAYS BEFORE EARNINGS REPORT, 19 WALL STREET ANALYSTS ARE FORECASTING $13.32 AKBA PRICE TARGET INDICATING 256.63% INCREASE. IMO THE FORECAST WILL NEED TO BE ADJUSTED UPWARD.

0 · Reply

Mr_Pithy Aug. 5 at 6:48 PM

$AKBA RECENT WHALE 🐳 ACTIVITY - 27 OUT OF 31 WHALES ARE BUYING AND HOLDING. NOT ALL WHALES 🐳 ARE PLAYING THRU EARNINGS THO’. SOME ARE CHICKENSHIT.

0 · Reply

Bulltrader988 Aug. 5 at 6:46 PM

$AKBA thursday pre market 👃👀

0 · Reply

Bidzill Aug. 5 at 6:39 PM

$AKBA Nearly symmetrical:

2 · Reply

Mr_Pithy Aug. 5 at 6:37 PM

2 · Reply

Solfer Aug. 5 at 6:35 PM

0 · Reply

Hogtrader1 Aug. 5 at 6:35 PM

$AKBA this is the most anticipated earnings release I can remember.

0 · Reply

Quinnlucky Aug. 5 at 6:26 PM

$AKBA If Q2 revenue hits $85M with as good as flat costs EPS could reach $0.13. That implies an annualized EPS of $0.52. With a modest multiple of 25 (I think this is justified with this growth rate) my px is $13- Note; Not a px target. A fair valuation.

0 · Reply

johnnytwotoes Aug. 5 at 6:21 PM

$AKBA 63M rev

3 · Reply